Tuesday, October 21, 2014

Rosetta Genomics in pact for thyroid cancer diagnostic

Rosetta Genomics in pact for thyroid cancer diagnostic

October 21, 2014 by · Leave a Comment 

Tweet Rosetta Genomics (NASDAQ:ROSG) has initiated a new public-private translational research project with the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool. The partnership was facilitated by the European Infrastructure for Translational Medicine (EATRIS) […]

HCW starts Oncothyreon at buy

HCW starts Oncothyreon at buy

October 21, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Oncothyreon (NASADQ:ONTY) with a “buy” rating and 12-month target price of $4, based on a risk-adjusted revenue and EPS multiples valuation methodology. The stock finished at $1.73 on Monday. “Oncothyreon’s biotechnology franchise is comprised of diverse set of therapeutics, including ONT-380, a potent and highly specific tyrosine kinase […]

Stifel starts Vitae Pharma at buy

Stifel starts Vitae Pharma at buy

October 20, 2014 by · Leave a Comment 

Tweet Stifel has initiated coverage of Vitae Pharmaceuticals (NASDAQ:VTAE) with a “buy” rating and price target of $14. The stock closed at $6.30 on Friday. “Vitae’s unique technology platform encompasses the unique ability to rationally design clinical candidates and represents the principal competitive advantage of the company,” writes analyst Dr. Brian Klein. He said Vitae’s CONTOUR […]

Nuvo Research sells U.S. Pennsaid 2% rights to Horizon


Nuvo Research sells U.S. Pennsaid 2% rights to Horizon


October 17, 2014 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) has sold the U.S. sales and marketing rights of its Pennsaid 2% topical pain reliever to Horizon Pharma (NASDAQ:HZNP) for a cash payment of $45-million. Effective Jan. 1, 2015, Horizon will assume U.S. commercialization of Pennsaid 2% from Nuvo’s former U.S. marketing licensee. Nuvo retains all rights to Pennsaid and Pennsaid […]

Novadaq signs India distribution deal with Kirloskar

Novadaq signs India distribution deal with Kirloskar

October 16, 2014 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has appointed Kirloskar Technologies as the exclusive distributor for its family of fluorescence imaging technologies in India. The relationship between the two companies officially kicked off today with a signing ceremony overseen by the Honourable Ed Fast, Canada’s Minister of International Trade, at the Taj Palace Hotel in New Delhi “NOVADAQ’s products […]

Roth adds MEI Pharma to Focus List, ups price target to $22

Roth adds MEI Pharma to Focus List, ups price target to $22

October 16, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has added “buy-rated” MEI Pharma (NASDAQ:MEIP) to its Focus List and raised its price target to $22 from $20. The stock closed at $7.68 on Wednesday. Analyst Joseph Pantginis writes that MEI is well positioned with its lead oral HDAC inhibitor, pracinostat, for the treatment of acute myeloid leukemia (AML) and […]

Verisante closes private placement

Verisante closes private placement

October 15, 2014 by · Leave a Comment 

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has closed a private placement of 2.5 million common shares at a price of 14 cents each for gross proceeds of $350,000. The private placement was made with Chinese investors who have entered into a previously announced letter of intent with Verisante. Under the terms of accord, the investors have […]

Cynapsus’ APL-130277 one of  “Top Ten Neurology Projects to Watch”

Cynapsus’ APL-130277 one of “Top Ten Neurology Projects to Watch”

October 14, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics’ (OTCQX:CYNAF; TSX-V:CTH) APL-130277 drug candidate for Parkinson’s disease has been recognized as one of the “Top Ten Neurology Projects to Watch” by a joint selection committee. The committee included Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain. Dr. Tracy is also the editor of the biotechnology publication, […]

GeneNews’ IDL adds blood test for breast cancer prediction

GeneNews’ IDL adds blood test for breast cancer prediction

October 14, 2014 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has in-licensed two biomarker assays – sphingotest pro-NT and sphingotest pro-ENK – that aid physicians in identifying those females at highest risk for breast cancer in the general population. Both tests were developed by sphingotec GmbH of Germany, a biomarker assay developer, which has recently expanded in the U.S. GeneNews expects to […]

Analysts launch coverage of Tokai Pharma

Analysts launch coverage of Tokai Pharma

October 13, 2014 by · Leave a Comment 

Tweet Analysts at William Blair, Stifel and Janney Capital Markets initiated coverage of Tokai Pharmaceuticals (NASDAQ:TKAI), saying its lead asset, galeterone, represents a first-in-class and best-in-class, selective and multi-targeted small molecule that should offer advantages over existing prostate cancer therapies. Analyst Katherine Xu started Tokai at “outperform” with a $44 price target. Shares of Tokai […]

Next Page »

Email Newsletters with Constant Contact
Google+